Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FBIO
stocks logo

FBIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
14.53M
-2.43%
--
--
21.02M
+43.68%
--
--
23.99M
+58.69%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Fortress Biotech, Inc. (FBIO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -25.88%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-25.88%
In Past 3 Month
Wall Street analysts forecast FBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBIO is 10.75 USD with a low forecast of 4.50 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBIO is 10.75 USD with a low forecast of 4.50 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.750
sliders
Low
4.50
Averages
10.75
High
17.00
Current: 2.750
sliders
Low
4.50
Averages
10.75
High
17.00
Alliance Global
Scott Henry
Buy
maintain
$4
2025-11-19
Reason
Alliance Global
Scott Henry
Price Target
$4
2025-11-19
maintain
Buy
Reason
Alliance Global analyst Scott Henry raised the firm's price target on Fortress Biotech to $4.50 from $4 and keeps a Buy rating on the shares following the Q3 report. The company's operating expenses are lower now in the absence of Checkpoint, the analyst tells investors in a research note.
H.C. Wainwright
Joseph Pantginis
Buy
downgrade
$26 -> $17
2025-08-21
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$26 -> $17
2025-08-21
downgrade
Buy
Reason
H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Fortress Biotech to $17 from $26 and keeps a Buy rating on the shares. The firm updated the company's model.
Roth Capital
Buy
downgrade
$15 -> $12
2025-08-19
Reason
Roth Capital
Price Target
$15 -> $12
2025-08-19
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Fortress Biotech to $12 from $15 and keeps a Buy rating on the shares after its Q2 results. The firm notes that with Journey's Emrosi launched, the recently completed sale of Checkpoint and a September PDUFA for CUTX-101, Fortress is well positioned to become a self-funding entity, the analyst tells investors in a research note. Roth adds however that its lower price target reflects a higher share count, lower market capitalizations of the company's public company portfolio, and lower probability of previously anticipated approval timing for CAEL-101.
Roth MKM
Jason Wittes
Strong Buy
Reiterates
$15 → $16
2025-03-11
Reason
Roth MKM
Jason Wittes
Price Target
$15 → $16
2025-03-11
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Fortress Biotech Inc (FBIO.O) is -1.71, compared to its 5-year average forward P/E of -3.51. For a more detailed relative valuation and DCF analysis to assess Fortress Biotech Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.51
Current PE
-1.71
Overvalued PE
2.01
Undervalued PE
-9.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.71
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.22
Undervalued EV/EBITDA
-1.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.46
Current PS
0.00
Overvalued PS
2.86
Undervalued PS
0.06
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

FBIO News & Events

Events Timeline

(ET)
2025-11-14
08:35:50
Fortress Biotech Announces Q3 EPS of 11 Cents Compared to a Loss of 76 Cents Last Year
select
2025-10-21 (ET)
2025-10-21
08:33:37
Fortress Subsidiary Reports Patient Dosed with Crystalys in Dotinurad Study
select
2025-10-01 (ET)
2025-10-01
08:26:36
Fortress Biotech and Urica Reveal $205M Series A Funding for Crystalys
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
10-24Newsfilter
Journey Medical Corporation Presents Efficacy Data Analysis from Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial at the 2025 Fall Clinical Dermatology Conference

  • FDA Approval and Efficacy: Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) is FDA-approved for treating inflammatory lesions of rosacea in adults, showing superior efficacy in clinical trials compared to both placebo and doxycycline.

  • Clinical Trial Results: In a pooled analysis of two Phase 3 trials, 62.7% of subjects treated with DFD-29 achieved treatment success, significantly outperforming the 39.0% success rate of Oracea and 28.2% for placebo, with notable reductions in inflammatory lesions.

  • Safety Profile: DFD-29 was well tolerated in trials, with no major safety issues reported, and the incidence of treatment-emergent adverse events was comparable across all treatment groups.

  • Market Position and Commitment: Journey Medical Corporation aims to expand Emrosi's market presence, emphasizing its potential as a standard treatment for rosacea and its commitment to improving patient outcomes in dermatology.

[object Object]
Preview
7.0
10-23PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Fortress Biotech Inc. and its officers/directors, urging affected investors to contact them.

  • FDA Response and Stock Impact: Fortress Biotech received a Complete Response Letter from the FDA regarding its New Drug Application for CUTX-101, citing manufacturing deficiencies, which led to a significant drop in its stock price by over 30%.

[object Object]
Preview
9.0
10-21Newsfilter
Fortress Biotech and Subsidiary Urica Therapeutics Report First Patient Doses in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for Gout Treatment

  • Clinical Trials Initiation: Urica Therapeutics announced the dosing of first patients in two Phase 3 trials (RUBY and TOPAZ) for dotinurad, a new oral treatment for gout, aiming to evaluate its safety and efficacy compared to allopurinol.

  • Significance of Trials: The initiation of these trials is seen as a crucial step towards expediting the development and regulatory approval of dotinurad, addressing a significant unmet need for patients with gout who do not respond to existing treatments.

  • Company Background: Urica is a subsidiary of Fortress Biotech, which has a diverse portfolio of pharmaceutical products and is focused on enhancing shareholder value through various revenue streams, including royalties from products like dotinurad.

  • Gout Overview: Gout is a common and debilitating form of arthritis caused by excess uric acid, leading to painful joint inflammation, with a notable treatment gap for patients who fail to respond to first-line therapies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Fortress Biotech Inc (FBIO) stock price today?

The current price of FBIO is 2.75 USD — it has increased 2.23 % in the last trading day.

arrow icon

What is Fortress Biotech Inc (FBIO)'s business?

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.

arrow icon

What is the price predicton of FBIO Stock?

Wall Street analysts forecast FBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBIO is 10.75 USD with a low forecast of 4.50 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Fortress Biotech Inc (FBIO)'s revenue for the last quarter?

Fortress Biotech Inc revenue for the last quarter amounts to 17.63M USD, increased 20.52 % YoY.

arrow icon

What is Fortress Biotech Inc (FBIO)'s earnings per share (EPS) for the last quarter?

Fortress Biotech Inc. EPS for the last quarter amounts to 0.11 USD, decreased -114.47 % YoY.

arrow icon

What changes have occurred in the market's expectations for Fortress Biotech Inc (FBIO)'s fundamentals?

The market is revising No Change the revenue expectations for Fortress Biotech, Inc. (FBIO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -25.88%.
arrow icon

How many employees does Fortress Biotech Inc (FBIO). have?

Fortress Biotech Inc (FBIO) has 101 emplpoyees as of December 05 2025.

arrow icon

What is Fortress Biotech Inc (FBIO) market cap?

Today FBIO has the market capitalization of 85.35M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free